Is Retatrutide FDA approved?
No — as of September 2026 retatrutide is not FDA-approved, and no application has been filed yet. Eli Lilly has reported positive results from three Phase 3 TRIUMPH trials and says it will submit a biologics license application in the first quarter of 2027. On a standard review timeline that puts an FDA decision in late 2027 at the earliest.
What retatrutide is
Retatrutide is Eli Lilly’s once-weekly injectable that acts on three receptors at once — GIP, GLP-1 and glucagon. Lilly positions it as the next pillar of its obesity franchise after tirzepatide (Zepbound) and its oral GLP-1, and it is being studied not only for obesity and type 2 diabetes but for knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic liver disease. None of those programs has produced an approval yet, in the US or anywhere else.
The Phase 3 record so far
Three TRIUMPH trials have read out positive. TRIUMPH-1 (May 2026) covered adults with obesity or overweight and at least one weight-related condition but no diabetes. TRIUMPH-2 (July 2026) covered obesity with type 2 diabetes and showed weight loss alongside improvement in blood-sugar control. TRIUMPH-3 (July 2026) covered severe obesity with established cardiovascular disease, with or without diabetes, and reported average weight loss of up to 22.6% — about 56 pounds — at 80 weeks, together with improvement in cardiovascular risk markers. Across the program the most common adverse events were diarrhea, nausea, constipation and decreased appetite, in line with the GLP-1 class. A long-term cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) continues, with completion estimated for 2029.
Why the filing slipped to 2027
Earlier in 2026 Lilly listed retatrutide among products it might submit by year-end. In July it moved the target to the first quarter of 2027, telling reporters it needed more time to assemble manufacturing and quality-control data for the agency. After submission, a standard FDA review runs about ten months; a priority review, if granted, about six. Either way, no decision is plausible before the second half of 2027, and a positive decision is not guaranteed.
What “not approved” means in practice
Until approval there is no labeled indication, no approved dose, no pharmacy supply and no legal compounding route — see our legal-status page for why. The single lawful path outside a trial is Lilly’s pre-approval expanded-access program, opened August 3, 2026, for a narrow group of patients whose physician applies on their behalf (NCT07629401). Products sold to consumers as retatrutide are not Lilly’s drug and sit outside the regulated supply.
When will retatrutide be approved?+
Is retatrutide approved anywhere outside the US?+
Is it more effective than tirzepatide or semaglutide?+
Can I get it before approval?+
Primary sources: Eli Lilly, “What to know about retatrutide” (updated July 2026) · ClinicalTrials.gov NCT07629401, pre-approval expanded access (status: Available, verified Aug 2026) · Lilly TRIUMPH-1/2/3 topline announcements (May and July 2026) · trade-press reporting on the Q1 2027 filing target and the expanded-access program (CNBC, BioPharma Dive, AJMC, July–August 2026).
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. Retatrutide is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.